The sleep supplement category is popular precisely because sleep problems are nearly universal. And that universality creates a compliance trap: when brands write for an audience of people who aren't sleeping well, the natural instinct is to write claims that speak to that experience — which often means crossing from structure/function claims about normal sleep support into disease claims about insomnia treatment.
What FDA Permits for Sleep Claims
Under 21 CFR 101.93(f), supplement labels may describe how ingredients affect the body's natural sleep processes. These structure/function claims are permitted:
"Supports healthy sleep"
"Promotes relaxation and restful sleep"
"Helps you fall asleep faster"
"Supports your natural sleep cycle"
"Promotes healthy sleep/wake cycles"
"Helps maintain healthy circadian rhythms"
"Supports relaxation before sleep"
"Promotes a sense of calm"
These describe support for normal sleep function in healthy individuals. They don't imply treatment of sleep disorders.
Where Sleep Claims Cross Into Disease Territory
Prohibited disease claims for sleep supplements:
"Treats insomnia" — insomnia is a classified sleep disorder
"Relieves chronic insomnia" — named condition
"For people who can't sleep" — implies treatment of a sleep disorder
"Restores normal sleep after anxiety" — references an anxiety disorder as the cause
"Treats sleep apnea" — named medical condition requiring medical device treatment
"Helps with sleep disruption caused by menopause" — menopause-related sleep disturbance references a specific clinical context
"Reduces nighttime awakenings caused by pain" — pain as a disease cause
"Clinically proven to add 45 minutes of sleep per night" — specific quantified outcome claims require FTC-standard evidence
"Helps you fall asleep faster" — how to frame it correctly
"Helps you fall asleep faster" is a structure/function claim when it describes support for normal sleep onset in healthy individuals. The same claim is a disease claim if the product is specifically marketed to people with insomnia or sleep disorders. The claim itself is the same; the context — who you're marketing to and what problem you're implying the product solves — determines its regulatory status.
Melatonin: A Special Case
Melatonin is the dominant sleep supplement ingredient and occupies a unique regulatory position. It is sold as a dietary supplement in the United States — but in many other countries, it is a prescription drug. This discrepancy reflects different regulatory frameworks, not different science.
In the U.S., melatonin has generally been accepted by the FDA as a dietary supplement ingredient based on its endogenous nature (it is naturally produced by the pineal gland). Structure/function claims for melatonin related to sleep onset and circadian rhythm support are generally accepted.
However, melatonin is also used in clinical contexts to treat specific conditions — jet lag disorder, delayed sleep phase syndrome, and others — and claims about treating these specific conditions are disease claims. A melatonin product marketed specifically for "delayed sleep phase disorder" is making a disease claim for a named condition.
Dose considerations for melatonin
The clinical evidence for melatonin is dose-dependent and largely supports effects at doses of 0.5 to 3mg — significantly lower than the 5-10mg doses commonly sold in the U.S. market. A claim about melatonin's sleep effects should reflect the evidence at the dose in your product. If your product contains 10mg and you're claiming sleep onset effects, the substantiation should support that dose.
L-Theanine, Magnesium, and Botanicals
L-theanine: Clinical evidence supports effects on relaxation and sleep quality. Structure/function claims about promoting relaxation and supporting sleep onset may be substantiated at appropriate doses.
Magnesium: Has evidence for roles in sleep regulation. Claims about supporting healthy sleep may be substantiated, particularly for forms with better bioavailability (glycinate, threonate).
Valerian root: Mixed clinical evidence. Structure/function claims are potentially supportable, but the evidence base is weaker than for melatonin and L-theanine.
Passionflower, lemon balm, chamomile: Weaker evidence bases. Claims should be carefully calibrated to what the evidence actually shows for the specific form and dose in your product.
Sleep Claims in Creator Content
Sleep supplement influencer marketing frequently produces the highest-risk claims in this category. Creators commonly describe personal experiences with insomnia, anxiety-related sleep problems, or chronic sleep disorders — and attribute their improvement to the product. These testimonials can constitute disease claims for which your brand is responsible under 16 CFR Part 255.
A creator saying "I've struggled with insomnia for years and this melatonin finally helped me sleep" is making an implied claim that the product treats insomnia — a disease claim. Truli's Social Monitoring flags these creator testimonials in real time so brands can address them before they attract FDA or FTC attention.
Sleep claims need to speak to healthy sleep, not sleep disorders
The most compliant sleep supplement marketing focuses on the experience of healthy sleep — falling asleep easily, sleeping soundly, waking rested — without implying that the product corrects a sleep disorder. Truli scans sleep supplement claims across labels, websites, ads, and creator content, flagging the disease-adjacent language that's easy to write and hard to defend.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
